Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease

被引:2
|
作者
Rabinovich-Guilatt, Laura [1 ]
Steiner, Lilach [2 ]
Hallak, Hussein [2 ]
Pastino, Gina [1 ]
Muglia, Pierandrea [3 ]
Spiegelstein, Ofer [4 ]
机构
[1] Teva Pharmaceut Ind Ltd, Clin Pharmacol & Pharmacometr, Malvern, PA USA
[2] Teva Pharmaceut Ind Ltd, Drug Metab & Pharmacokinet, Netanya, Israel
[3] Neurosci Discovery Med UCB Pharma Chemin Foriest, Brussels, Belgium
[4] Teva Pharmaceut Ind Ltd, Clin Pharmacol & Pharmacometr, Netanya, Israel
关键词
CYP2D6; drug interactions; pridopidine; TV-45065; IN-VITRO; CONCISE GUIDE; TOLERABILITY PROFILE; PHARMACOLOGY; PHARMACOKINETICS; HEPATOCYTES; (-)-OSU6162; RECEPTORS; INDUCTION; ENZYMES;
D O I
10.1111/bcp.13317
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease. This study examined the interactions of pridopidine with in vitro cytochrome P450 activity and characterized the effects of pridopidine on CYP2D6 activity in healthy volunteers using metoprolol as a probe substrate. The effect of food on pridopidine exposure was assessed. METHODS The ability of pridopidine to inhibit and/or induce in vitro activity of drug metabolizing enzymes was examined in human liver microsomes and fresh hepatocytes. CYP2D6 inhibition potency and reversibility was assessed using dextromethorphan. For the clinical assessment, 22 healthy subjects were given metoprolol 100mg alone and concomitantly with steady-state pridopidine 45mg twice daily. Food effect on a single 90mg dose of pridopidine was evaluated in a crossover manner. Safety assessments and pharmacokinetic sampling occurred throughout the study. RESULTS Pridopidine was found to be a metabolism dependent inhibitor of CYP2D6, the main enzyme catalysing its own metabolism. Flavin-containing monooxygenase heat inactivation of liver microsomes did not affect pridopidine metabolism-dependent inhibition of CYP2D6 and its inhibition of CYP2D6 was not reversible with addition of FeCN3. Exposure to metoprolol was markedly increased when coadministered with pridopidine; the ratio of the geometric means (90% confidence interval) for maximum observed plasma concentration, and area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and extrapolated to infinity were 3.5 (2.9, 4.22), 6.64 (5.27, 8.38) and 6.55 (5.18, 8.28), respectively. Systemic exposure to pridopidine was unaffected by food conditions. CONCLUSIONS As pridopidine is a metabolism-dependent inhibitor of CYP2D6, systemic levels of drugs metabolized by CYP2D6 may increase with chronic coadministration of pridopidine. Pridopidine can be administered without regard to food.
引用
收藏
页码:2214 / 2224
页数:11
相关论文
共 50 条
  • [1] A drug-drug interaction study of pridopidine, a new drug for treatment of Huntington's disease, and metoprolol, a cytochrome P450 2D6 substrate
    Rabinovich-Guilatt, L.
    Wickenberg, A.
    Bassan, M.
    Spiegelstein, O.
    MOVEMENT DISORDERS, 2014, 29 : S213 - S213
  • [2] The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
    Rabinovich-Guilatt, L.
    Siegler, K. E.
    Schultz, A.
    Halabi, A.
    Rembratt, A.
    Spiegelstein, O.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (02) : 246 - 255
  • [3] Pridopidine for the treatment of Huntington's disease
    Shannon, Kathleen M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 485 - 492
  • [4] Pridopidine in the treatment of Huntington's disease
    Jablonska, Magdalena
    Grzelakowska, Klaudyna
    Wisniewski, Bartlomiej
    Mazur, Ewelina
    Leis, Kamil
    Galazka, Przemyslaw
    REVIEWS IN THE NEUROSCIENCES, 2020, 31 (04) : 441 - 451
  • [5] Pridopidine for the Treatment of Early Huntington's Disease
    Geva, M.
    Reilmann, R.
    Olanow, C.
    Leinonen, M.
    Cohen, Y.
    Meyer, P.
    McGarry, A.
    Sabri, O.
    Hayden, M.
    Kieburtz, K.
    MOVEMENT DISORDERS, 2020, 35 : S99 - S99
  • [6] Pridopidine in treatment of Huntington's disease: beyond chorea?
    Feigin, Andrew
    LANCET NEUROLOGY, 2011, 10 (12): : 1036 - 1037
  • [7] The effect of renal impairment on the pharmacokinetics of pridopidine, a new dopamine stabilizer for treatment of Huntington's disease
    Rabinovich-Guilatt, L.
    Siegler, K. E.
    Schultz, A.
    Halabi, A.
    Rembratt, A.
    Wickenberg, A.
    Spiegelstein, O.
    MOVEMENT DISORDERS, 2014, 29 : S213 - S214
  • [8] STUDY FOR DRUG-DRUG INTERACTION IN THE TREATMENT OF CHRONIC DISEASE
    Chae, Jung-Woo
    Beak, Hyun-Moon
    Song, Byung-Jeong
    Lee, Byung-Yo
    Kang, Ho-Il
    Kwon, Kwang-Il
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 50 : E205 - E205
  • [9] Drug-drug Interaction in the Treatment of Gastrointestinal Tumors
    Yang, Jun-Xiong
    LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (09): : 1784 - 1788
  • [10] Pridopidine, a Highly Selective S1R Agonist for the Treatment of Huntington Disease
    Geva, Michal
    Raymond, Lynn
    Ross, Chris
    Rego, Ana Cristina
    Saudou, Frederic
    Bezprozvanny, Ilya
    Hayden, Michael
    NEUROTHERAPEUTICS, 2019, 16 (04) : 1360 - 1361